Tagged with Opinion,

Global HEOR is transforming healthcare decision-making by evaluating treatment costs, patient quality of life, and overall value, helping stakeholders make informed choices. ISPOR’s new “HEOR Explained” website simplifies these complex concepts to promote wider understanding and application of real-world evidence and ultimately drive more effective and sustainable healthcare.   In today’s…

Japan Japan’s amended Cannabis Control Law now permits the development and medical use of cannabis-derived drugs, particularly CBD-based treatments, while simultaneously criminalizing self-use of smokable cannabis products. Writing in the February 2024 edition of DIA’s Global Forum magazine, Toshi Tominaga of Keio University explains why, despite aligning with evolving international regulations,…

Europe The EMA’s Pre-Accession Assistance Program (IPA) helps EU candidate and potential candidate countries align their medicines regulations with EU standards through training, capacity-building, and policy support. As a new op-ed in the February 2025 edition of DIA’s Global Forum magazine outlines, an impact assessment of IPA II (2020-2023) showed significant…

Africa Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties that wealthier countries rarely experience.   African countries face a difficult choice during outbreak situations. On one hand, they have…

Global Regular PharmaBoardroom contributor David H. Crean outlines the resilient and cautious optimism observed at JPM 2025, the annual healthcare financing conference held near San Francisco’s Union Square. While uncertainties and headwinds still persist, particularly around regulatory changes, affordability issues, and capital financing in the public and private markets, the healthcare…

Global Drawing on insights from DIA’s 2024 Global Annual Meeting, Martin Hodosi and Rosanna Lim of Kearney Healthcare and Life Sciences examine some of the key ethical challenges around integrating AI into healthcare.   Artificial intelligence (AI) has already begun transforming the healthcare industry, with applications ranging from diagnostics to drug…

Europe James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe.   In an era where artificial intelligence (AI) is revolutionizing healthcare and clinical research, regulatory bodies are racing to keep pace. The…

Global Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.   As pharma companies gear up for another year – a year that marks a quarter of the way through…

India Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for pharmaceuticals are impacting the industry.   Since 2001, the regulatory environment for clinical research and drug development in India has…

Africa John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into Africa have yet to reach fruition.   Recent pandemics have triggered calls for deglobalization in the production of medical products…

Global IFPMA represents the innovative pharmaceutical industry at the international level and in official relations with the United Nations. Dr David Reddy joined the association earlier this year, and shares his analysis on how vaccines and treatments are transforming health outcomes for people around the world, and how the pipeline of…

Global Scott D. Ramsey of the Fred Hutchinson Cancer Center discusses the trend driving pharmaceutical companies to reorganize or eliminate their health economics and outcomes research (HEOR) groups. The original version of this article was featured in the September/October edition of ISPOR’s Value & Outcomes Spotlight magazine.   Last spring, I had…